The following represents disclosure information provided by authors of this abstract. The program committee has reviewed all presenting author disclosure reports, identified potential conflicts of interest, and implemented strategies to manage those areas of conflict, where appropriate. All relationships are considered compensated. Relationships are self-held unless otherwise noted. I = Immediate Family Member, Inst = My Institution
 
Open Payments is a public database containing information reported by companies about payments made to US-licensed physicians (Open Payments)
Adjuvant study of amcenestrant (SAR439859) versus tamoxifen for patients with hormone receptor-positive (HR+) early breast cancer (EBC), who have discontinued adjuvant aromatase inhibitor therapy due to treatment-related toxicity (AMEERA-6).
 
Thomas Meyskens
No Relationships to Disclose
 
Otto Metzger
Stock and Other Ownership Interests - Invitae
Honoraria - Grupo Oncoclinicas; Merck
Consulting or Advisory Role - Alliance for Clinical Trials in Oncology; Grupo Oncoclinicas; Resilience Care
Speakers' Bureau - AstraZeneca
Research Funding - Abbvie (Inst); Cascadian Therapeutics (Inst); Eisai (Inst); Pfizer (Inst); Roche/Genentech (Inst); Susan G. Komen for the Cure (Inst)
Patents, Royalties, Other Intellectual Property - Sanofi (Inst)
Travel, Accommodations, Expenses - Grupo Oncoclinicas
 
Coralie Poncet
No Relationships to Disclose
 
Theodora Goulioti
Employment - UCB (I)
Stock and Other Ownership Interests - GlaxoSmithKline (I); UCB (I)
Research Funding - AstraZeneca (Inst); Biovica (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); SERVIER (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - My institution receives royalties from Agendia for MammaPrint, due to the collaboration on the conduct of the MINDACT trial (Inst)
 
Eleni Xenophontos
No Relationships to Disclose
 
Lisa A. Carey
Research Funding - Abbvie (Inst); NanoString Technologies (Inst); Novartis (Inst); Seagen (Inst); Syndax (Inst); Veracyte (Inst)
Patents, Royalties, Other Intellectual Property - Royalty-sharing agreement, investorship interest in licensed IP to startup company, Falcon Therapeutics, that is designing neural stem cell-based therapy for glioblastoma multiforme. (I)
(OPTIONAL) Uncompensated Relationships - Aptitude Health (Inst); AstraZeneca/Daiichi Sankyo (Inst); Eisai; Exact Sciences (Inst); G1 Therapeutics (Inst); Genentech/Roche (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Sanofi (Inst)
 
Lei Wang
Employment - Sanofi
Stock and Other Ownership Interests - Ikena Oncology; Syndax
 
Giovanna Rossi
Research Funding - AstraZeneca (Inst); Biovica (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); Sanofi/Aventis (Inst); SERVIER (Inst); Tesaro (Inst)
Patents, Royalties, Other Intellectual Property - My institution receives royalties from Agendia for MammaPrint, due to the collaboration on the conduct of the MINDACT trial. (Inst)
 
Leslie Gilham
Consulting or Advisory Role - Roche/Genentech
Other Relationship - Breast Cancer Trials Australia and New Zealand
 
Heidi De Swert
Research Funding - AstraZeneca; BIOVICA; GlaxoSmithKline; Novartis; Pfizer; Roche/Genentech; Sanofi/Aventis; Servier; Tesaro
Patents, Royalties, Other Intellectual Property - Agendia (Inst)
 
Jose Casas-Martin
No Relationships to Disclose
 
Elham Attieh
Employment - Clemenceau Medical Center
 
Amal Arahmani
Research Funding - AstraZeneca (Inst); BIOVICA (Inst); GlaxoSmithKline (Inst); Novartis (Inst); Pfizer (Inst); Roche/Genentech (Inst); SANOFI (Inst); SERVIER (Inst); TESARO (Inst)
Patents, Royalties, Other Intellectual Property - Agendia (Inst)
 
Laura De Meulemeester
No Relationships to Disclose
 
Ann H. Partridge
Patents, Royalties, Other Intellectual Property - I receive small royalty payments for co-authoring the breast cancer survivorship section of UpToDate
 
Christina Isabella Herold
Employment - Sanofi
Stock and Other Ownership Interests - Sanofi
Travel, Accommodations, Expenses - Sanofi
 
Gautier Paux
Employment - Sanofi
 
Amylou C. Dueck
Patents, Royalties, Other Intellectual Property - Royalties from licensing fees for a patient symptom questionnaire (MPN-SAF)
 
Etienne Brain
Honoraria - Lilly; Pfizer; Pfizer; Seagen
Consulting or Advisory Role - Daiichi Sankyo/Astra Zeneca; Pfizer; Pfizer; Sandoz-Novartis
Travel, Accommodations, Expenses - Pfizer; Pfizer; Pfizer; Pfizer
 
David A. Cameron
Consulting or Advisory Role - Clarity Pharmaceuticals (Inst); Daiichi Sankyo (Inst); Eisai (Inst); Lilly (Inst); Merck Sharp & Dohme (Inst); Novartis (Inst); Novartis (Inst); Oncolytics (Inst); Pfizer (Inst); Prima BioMed (Inst); Puma Biotechnology (Inst); Research Triangle Institute RTI Health Solutions (Inst); Roche (Inst); Roche (Inst); Samsung Bioepis (Inst); Sanofi (Inst); Seagen (Inst); Synthon (Inst); Zymeworks (Inst); Zymeworks (Inst)
Research Funding - AstraZeneca (Inst); Novartis (Inst); Roche (Inst)